Relief Cardiovascular

Relief Cardiovascular is an early-stage innovator targeting a significant unmet need in heart failure: diuretic-resistant volume overload. The company is pioneering a new category of transcatheter, smart implant systems that combine autonomous hemodynamic monitoring with the ability to modulate venous return (preload) to improve decongestion. Backed by specialized cardiovascular investors and led by an experienced team, Relief aims to move beyond temporary solutions and pharmaceuticals to offer a durable, personalized, and adjustable device therapy. Its first-generation Relief System has entered initial clinical studies outside the United States, positioning the company at the forefront of next-generation heart failure device development.

Transcatheter smart implant systems combining autonomous hemodynamic monitoring with active venous return (preload) modulation, initially targeting the inferior vena cava.

Direct competition is currently limited, as permanent transcatheter IVC modulators do not exist. Temporary IVC modulator catheters (e.g., from companies like Vectorious) are indirect competitors but also serve as market validators. The primary competitive backdrop is the standard of care: diuretic pharmaceuticals and, for advanced cases, heart transplants or ventricular assist devices. Larger medtech firms may enter the space if the approach gains validation.